ABL Bio secures $55 million from Eli Lilly to accelerate Grabody platform development
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
The study met its primary endpoint with flying colors
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Subscribe To Our Newsletter & Stay Updated